Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2007-08-14
2007-08-14
Tucker, Zachary C. (Department: 1624)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C544S252000
Reexamination Certificate
active
11061144
ABSTRACT:
Novel pyrimidoindolone compounds are disclosed. Methods of using the pyrimidoindolone compounds and compositions containing the compounds in the treatment and/or prevention of disease and other conditions related to inflammation, neurodegeneration, osteoarthritis and apoptosis are also disclosed.
REFERENCES:
patent: 3891644 (1975-06-01), White
patent: 4784996 (1988-11-01), White et al.
patent: 0 987 027 (2000-03-01), None
patent: 1 520 611 (1978-08-01), None
patent: 2 187 738 (1987-09-01), None
patent: 2 187 739 (1987-09-01), None
patent: 95/13807 (1995-05-01), None
patent: 99/06042 (1999-02-01), None
patent: 99/06367 (1999-02-01), None
patent: 00/18769 (2000-04-01), None
patent: 00/18769 (2000-04-01), None
patent: 00/61159 (2000-10-01), None
Banker, Gilbert S. et al., Modem Pharmaceutics, Marcel Dekker, New York, 1996.
Wolff, Manfred E., Burger's Medicinal Chemistry and Drug Discovery, Fifth Ed., vol. 1: Principles and Practice, John Wiley & Sons, 1995, 975.
Gaur, Upasna, et al., Regulation of Proliferation, Survival and Apoptosis by Members fo the TNF Superfamily, Biochemical Pharmacology 66, 2003, 1403-1408.
Supuran, Claudiu T. Supuran, Protease Inhibitors of the Sulfonamide Type: Anticancer, Antiinflammatory, and Antiviral Agents, Medicinal Research Reviews, vol. 23, No. 5, 535-558, 2003.
Portnov, et al., Mosk. Gos. Univ. im. Lomonosova, Moscow, USSR Khimiya Geterotsiklicheskikh Soedinenii (1973), (5), 647-52.
Chen, J. et al., “Induction of Caspase-3-Like Protease May Mediate Delayed Neuronal Death in the Hippocampus after Transient Cerebral Ischemia,”J. Neuroscience, 18(13): 4914-4928 (1998).
Krupinski, J. et al., “Expression of Caspases and Their Substrates in the Rat Model of Focal Cerebral Ischemia,”Neurobiol. Dis.7: 332-342 (2000).
Benchoua, A et al., “Specific Caspase Pathways Are Activated in the Two Stages of Cerebral Infarction,”J. Neuroscience21(18): 7127-7134 (2001).
Namura, S. et al., “Activation and Cleavage of Caspase-3 in Apoptosis Induced by Experimental Cerebral Ischemia,”J. Neuroscience.18(10): 3659-3668 (1998).
Yaoita, H. et al., “Attenuation of Ischemia/Reperfusion Injury in Rats by a Caspase Inhibitor,”Circulation, 97: 276-281 (1998).
Endres, M. et al., “Attenuation of Delayed Neuronal Death After Mild Focal Ischemia in Mice by Inhibition of the Caspase Family,”J. Cerebral Blood Flow and Metabolism, 18: 238-247 (1998).
Cheng, Y. et al., “Caspase Inhibitor Affords Neuroprotection with Delayed Administration in a Rat Model of Neonatal Hypoxic-Ischemic Brain Injury,”J. Clin. Invest., 101(9):1992-1999 (May 1998).
Yakovlev, A. G. et al., Activation of CPP32-Like Caspases Contributes to Neuronal Apoptosis and Neurological Dysfunction after Traumatic Brain Injury,J. Neuroscience, 17(19): 7415-7424 (1997).
Rodriquez, I. et al., “Systemic Injection of a Tripeptide Inhibits the Intracellular Activation of CPP32-like Proteases in Vivo and Fully Protects Mice against Fas-mediated Fulminant Liver Destruction and Death,”J. Exp. Med., 184: 2067-2072 (1996).
Grobmyer, S. R. et al., “Peptidomimetic Fluoromethylketone Rescues Mice from Lethal Endotoxic Shock,”Mol. Med., 5: 585-594 (1999).
Pelletier, J-P. et al., “Selective Inhibition of Inducible Nitric Oxide Synthase Reduces Progression of Experimental Osteoarthritis in Vivo,”Arthritis&Rheumatism, 43(6):1290-1299 (2000).
Chan, H. K., “Application of polarography to the development of a stability-indicating assay method for a new indole derivative and its tablet formulations,”J. Pharmacy and Pharmacology1974, 26, Suppl:37P-40P.
Cliffe, I. A. et al., “Oral Hypoglycemic Agents. Pyrimido[1,2-a]indoles and Related Compounds,”J. Med Chem., Apr. 3, 1992, 35(7): 1169-1175.
Portnov, Y. N. et al., “Chemistry of Indole XXXVI. Rearrangement of 1-Phynyl-2-Acetylhydrazines and 1-Phenyl-2-Acetylpyrazolidines,”Chemistry of Heterocyclic Compounds, 1973, 9:598-602.
Brown, D. G. et al., “Microwave-Assisted Synthesis of Heterocycles for Expedient Drug Discovery: Applications in Hit-to-Lead Discovery,” Mid-Atlantic Symposium on Microwave Assisted Organic Synthesis, AstraZeneca Pharmaceuticals, 2003.
Lee, D. et al., “Potent and Selective Nonpeptide Inhibitors of Caspases 3 and 7,”J Med Chem, 2001, 44:2015-2026.
Lee, D. et al., “Potent and Selective Nonpeptide Inhibitors of Caspases 3 and 7 Inhibit Apoptosis and Maintain Cell Functionality,”J Bio Chem, 2000, 275(21): 16007-16014.
Popp, F. D.,Advances in Heterocyclic Chemistry, 1975, 18: 1-58.
Sandmeyer, T.,Helvetica. Chim. Acta, 1919, 2: 234-242.
T.W. Greene and P.G.M. Wuts, “Protective Groups in Organic Synthesis,” 2nded. John Wiley and Sons, New York, NY, Chapter 4.
Cliffe, I. A., “Synthesis of 2,2-Dialkyl-3-Halopropanenitriles from 2,2-Dialkylethanenitriles and Dihalomethanes,”Syn Comm., 20(12) 1757-1767, 1990.
Mitsunobu, O., “The Use of Diethyl Azodicarboxylate and Triphenylphosphine in Synthesis and Transformation of Natural Products,”Synthesis, 1981, 1-27.
Hewawasam, P. et al., “A General Method for the Synthesis of Isatins: Preparation of Regiospecifically Functionalized Isatins from Anilines,”Tetrahedron Letters, 1994, 35(40): 7303-7306.
Thornbery, N.A., et al., “A Combinatorial Approach Defines Specificities of Members of the Caspase Family and Granzyme B,”J. Biol. Chem.1997 272(29) 17907-17911.
Stennicke, H. R. et al., “Biochemical Characteristics of Caspases-3, -6, and -8,”J. Biol. Chem.1997 272(41) 25719-25723.
Bundgaard, H. (ed.),Design of Prodrugs, Elsevier (1985), Ch. 1 (pp. 1-92), Ch. 4 (pp. 157-176), Ch. 5 (pp. 177-198), and Ch. 6 (pp. 199-241).
Widder, et al. (ed.),Methods in Enzymology, vol. 112, Academic Press (1985), pp. 309-396.
Krogsgaard-Larsen, et al. (ed.), “Design and Application of Prodrugs”, Textbook of Drug Design and Development, Chapter 5, 113-191 (1991).
Bundgaard, H., “Means to enhance penetration; Prodrugs as a means to improve the delivery of peptide drugs,”Advanced Drug Deliver Reviews, 1992, 8, 1-38.
Bundgaard, H. et al., “Glycolamide Esters as Biolabile Prodrugs of Carboxylic Acid Agents: Synthesis, Stability, Bioconversion, and Physicochemical Properties,”J. of Pharmaceutical Sciences, Apr. 1988, 77(4):285-298.
Higuchi and Stella (eds.),Prodrugs as Novel Drug Delivery Systems, American Chemical Society (1975), pp. 1-115 and 196-223.
Fujita, S., “A Convenient Preparation of Arenesulfonyl Chlorides from the Sodium Sulfonates and Phosphoryl Chloride/Sulfolane,”Synthesis, May 1982, pp. 423-424.
Kravchenko, D. V. et al., “Synthesis and Structure-Activity Relationship of 4-Substituted 2-(2-Acetyloxyethyl)-8 (morpholine-4-sulfonyl)pyrrolo[3,4-c]quinoline-1,3-diones as Potent Caspase-3 Inhibitors,”J Med Chem, 2005, 48(11):3680-3683.
Kravchenko, D. V. et al., “1,3-Dioxo-4-methyl-2,3-dihydro-1 H-pyrrolo[3,4-c]quinolines as potent caspase-3 inhibitors,”Bioorganic&Medicinal Chemistry Letters, 2005, 15(7):1841-1845.
Bicksler James Jacob
Childers Wayne Everett
Chong Chae-Koo Dan
Dietrich Arlene Joan
Dollings Paul Jeffrey
Leeser Erich A.
Tucker Zachary C.
Woodcock & Washburn LLP
Wyeth
LandOfFree
Pyrimidoindolones and methods for using same does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Pyrimidoindolones and methods for using same, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Pyrimidoindolones and methods for using same will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3871694